New cell therapy JY231 targets tough leukemia in early human test
NCT ID NCT06514768
First seen Jan 08, 2026 · Last updated May 08, 2026 · Updated 21 times
Summary
This early-phase study tests a new treatment called JY231 for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. The main goals are to check safety and find the right dose. About 20 adults whose cancer has CD19 on their cells can join. This is a first step to see if the therapy is safe and might work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
920th HJointLogistics
RECRUITINGKunming, Yunnan, China
Conditions
Explore the condition pages connected to this study.